A study to evaluate the safety of GlaxoSmithKline HPV-16/18 L1 VLP AS04 vaccine who received the placebo control in the GSK HPV-015 study

Update Il y a 4 ans
Reference: EUCTR2010-020227-48

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess the safety of the HPV-16/18 L1 VLP AS04 vaccine throughout the study period.


Inclusion criteria

  • Cervarix is indicated in females from 10 years of age onwards for the prevention of premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18 ,In addition, Cervarix has shown efficacy against persistent infection caused by oncogenic HPV types other than HPV-16 and HPV-18

Links